AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00960115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A single dose of saline (sodium chloride, 9 grams per liter \[g/L\]) will be administered intravenously, 3 days prior to the start of placebo.
Study NCT01400386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee bioavailability trial
Description: Coffee bioavailability trial
Study NCT02401802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
Study NCT00352859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon
Description: Continue sorafenib with addition of gemcitabine or interferon
Study NCT00352859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine or Interferon (only)
Description: Discontinue Sorafenib and receive Gemcitabine or Interferon only
Study NCT02328521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
Study NCT02328521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicorandil placebo
Description: Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
Study NCT01082848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: 10 mg QD during 26 weeks
Study NCT01082848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: QD during 26 weeks
Study NCT02950103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphoethanolamine
Description: Phosphoethanolamine PO daily
Study NCT01100281 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological examination
Description: Examination including especially concept formation
Study NCT02787603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interruption of antibiotic treatment due to PCT measurement
Description: In group A at day 5, if the patient shows no clinical signs of infection and PCT levels \< 0,25ng/mL OR PCT > 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
Study NCT01100281 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI performed in T1-weighted three dimensional sequence
Study NCT04081376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: 4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
Study NCT01566058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BB Box available
Description: The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
Study NCT01566058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No BB Box
Description: The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
Study NCT02862548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet administered orally
Study NCT02862548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Tablet administered orally
Study NCT02862548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other approved antivirals
Description: Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
Study NCT04851002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of concentrated growth factor with dental implants
Description: Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
Study NCT01273571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Metformin
Description: Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
Study NCT01680926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almased
Description: During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
Study NCT03841942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinically-based spacing strategy
Description: All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
Study NCT03841942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trough level-based strategy
Description: patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
Study NCT02844985 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT01419119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol high dose at Vitamin D deficiency
Description: 10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
Study NCT01419119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol median dose at Vitamin D insufficiency
Description: 2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
Study NCT01419119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol low dose at Vitamin D deficiency
Description: 2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
Study NCT01419119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol median dose at sufficient Vitamin D level
Description: 2000 IU daily i.e. 3 drops orally once daily for 12 weeks
Study NCT04851002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of advanced platelet rich fibrin with dental implants
Description: Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant
Study NCT04851002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of concentrated growth factor study group
Description: Traditional implant methods applied
Study NCT02625181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated recommendation at the start of the case
Description: The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
Study NCT04851002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of advanced platelet rich fibrin study group
Description: Traditional implant methods applied
Study NCT05101395 — intervention group
Intervention type: OTHER
Intervention: Giemsa stain
Description: Giemsa special stain was employed for detection of H. Pylori microorganisms.
Study NCT03400215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Breast Cancer Scan
Description: clinically indicated diagnostic breast MRI scans
Study NCT02625181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated notification at the start of surgery
Description: The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
Study NCT02625181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative recommendations: by email
Description: A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
Study NCT02625181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated notification at the end of surgery
Description: A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
Study NCT03400215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Description: 15-min research MRI scan
Study NCT02625181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Information Management System (AIMS)
Description: The anesthesia electronic record keeping system
Study NCT02625181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioperative Data Warehouse (PDW)
Description: The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
Study NCT02625181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
Study NCT02625181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective surgery
Description: Surgical procedures that are scheduled and not an emergency.
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Prophylactic antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Analgesic drug / Opioid
Study NCT01047748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-fetal digoxin injection
Description: Single transabdominal injection of digoxin 1 mg into the fetus
Study NCT01047748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-amniotic digoxin injection
Description: Single transabdominal injection of digoxin 1 mg into the amniotic fluid
Study NCT03823599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile chat-based instant messages
Description: Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
Study NCT03823599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol brief intervention
Description: The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
Study NCT03823599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol brief intervention
Description: The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
Study NCT00709917 — intervention group
Intervention type: DRUG
Intervention: repaglinide
Description: Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
Study NCT01025011 — intervention group
Intervention type: DEVICE
Intervention: Fundus photography, cubital blood draw
Description: blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
Study NCT02451202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Blockade
Description: * During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~* At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2.
Study NCT02451202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Neuromuscular Blockade
Description: - During maintenance phase, if recovery at the presence of \<10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Analgesic drug / Opioid
Study NCT02451202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Analgesic drug / Opioid
Study NCT02451202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Study NCT02451202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study NCT02451202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT01303432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with Mobilee
Description: One yogurt (125mL) per day including 80mg of Mobilee
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Description: Analgesic drug / Opioid
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Analgetic / Analgesic drug
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT01303432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt
Description: One yogurt (125mL) per day
Study NCT03555240 — intervention group
Intervention type: OTHER
Intervention: Biobank creation and Pharmacogenetic analysis
Description: Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
Study NCT01230749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
Study NCT01230749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
Study NCT01230749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
Study NCT01230749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
Study NCT01230749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
Study NCT04437030 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MSOT Acuity Echo device
Description: The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
Study NCT04437030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSOT Acuity Echo device
Description: The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
Study NCT01279304 — intervention group
Intervention type: RADIATION
Intervention: radiation - no radiation see intervention description
Description: after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
Study NCT01279304 — intervention group
Intervention type: RADIATION
Intervention: radiation: see intervention description
Description: after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
Study NCT01279304 — intervention group
Intervention type: RADIATION
Intervention: radiation: see intervention description
Description: after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
Study NCT05113719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will perform bridge exercise
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT02625181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Prophylactic antiemetic \& rescue antiemetic
Study NCT00839423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, daily, orally
Study NCT00839423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally
Study NCT00839423 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine XL
Description: capsules, daily, orally
Study NCT01234493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation
Description: Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
Study NCT01234493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no fixation
Description: No syndesmosis fixation.